Comparison of hypotensive response to aggregated IgG or to bacterial LPS in rats

Inflammation Research

Volumn 46, Issue 8, 1997, Pages 287-291

  Jenei, B ^a   Pocsik E ^b   Lazar G ^c   Medgyesi, G A ^a  

^a Ctrl Inst of Hung Natl Blood T   (Hungary)

^b National Institute of Haematology and Immunology Budapest   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Aggregated IgG; Gadolinium chloride; Hypotension; LPS; TNF

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GADOLINIUM CHLORIDE; IMMUNOGLOBULIN G; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HYPOTENSION; IMMUNOGLOBULIN AGGREGATE; INTRAVENOUS DRUG ADMINISTRATION; MACROPHAGE; NONHUMAN; RAT;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; FEMALE; GADOLINIUM; HYPOTENSION; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MALE; MICE; PENTOXIFYLLINE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030815630     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050189     Document Type: Article

References (29)

1. Weigle WO, Cochrane CG, Dixon FJ. Anaphylactic properties of soluble antigen-antibody complexes in the guinea pig and rabbit. J Immunol 1960;85:469-78.
2. Inarrea P, Alonso F, Sanchez Crespo M. Platelet activating factor: An effector substance of the vaso-permeability changes induced by the infusion of immune aggregates in the mouse. Immunopharmacology 1983;6:7-14.
3. Sanchez Crespo M, Fernandez-Galliardo S, Nieto ML, Barnes J, Braquet P. Inhibition of vascular actions of IgG aggregates by BN 5201, a highly specific antagonist of PAF-acether. Immunopharmacology 1985;10:69-75.
4. Doebber TW, Wu MS, Rohbins JC, Choy BM, Chang MN, Shen TY. Platelet activating factor PAF; involvement in endotoxin induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochim Biophys Res Commun 1985;127:799-808.
5. Terashita Z, Imura Y, Nishikawa K, Sumida S. Is platelet activating factor PAF a mediator of endotoxin shock? Eur J Pharmacol 1985;109:257-61.
6. Chang S-W, Fedderson CO, Henson PM, Voelkel NF. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987;79:1498-509.
7. Sanchez Crespo M, Alonso F, Egido J. Platelet activating factor in anaphyalxis and phagocytosis. I. Release from human polymorphonuclears and monocytes during phagocytosis and by ionophore A 23187, but not from degranulating hasophils. Immunology 1980;40:645-55.
8. Bleeker WK, Agterberg J, Rigter G. de Vries-van Rossen A, Bakker JC. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol 1989;77:338-44.
9. Husztik E. Lázár G, Párducz Á. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Path 1980;61:624-30.
10. Lázár G, van Galen M, Scherphof GL. Gadolinium chloride-induced shifts in intrahepatic distributions of liposomes. Biochim Biophys Acta 1989;1011:97-101.
11. Freudenberg MA, Galanos C. Bacterial lipopolysaccharides: Structure, metabolism and mechanics of action. Int Rev Immunol 1990;6:207-21.
12. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol 1996;60:8-26.
13. Fahmi H, Ancuta P, Perrier S, Chaby R. Preexposure of mouse peritoneal macrophages to lipopolysaccharide and other stimuli enhances the nitric oxide response to secondary stimuli. Inflamm res 1996;45:347-56.
14. Bleeker WK, Agterberg J, Rigter G, de Vries-van Rossen A, Bakker JC. An animal model for the detection of hypotensive side effects of immunoglobulin preparations. Vox Sang 1987;52:281-90.
15. Jenei B, Lázár G, Bartha K, Mihalik R, Medgyesi GA. Hypotensive action of aggregated IgG rats. Study of the responsiveness to a second dose following restoration of the blood pressure. Agents Actions 1994;42:63-6.
16. Jenei B, Lázár G, Bartha K, Medgyesi GA. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF receptor antagonist BN 52021 and by gadolinium chloride: an agent blocking Kupffer cell function. Agents Actions 1991;32:333-8.
17. Aggarwal BB, Kohr WJ, Mass PE, Moffat B, Spencer SA, Henzel WJ, et al. Human tumor necrosis factor. Production, purification and characterization. J Biol Chem 1985;260:2345-54.
18. Buxton DB, Hanahan DJ, Olson MS. Stimulation of glycogenolysis and platelet-activating factor production by heat-aggregated immunoglobulin G in the perfused rat liver. J Biol Chem 1984;259:13758-71.
19. Doebber TW, Wu MS, Biftu T. Platelet activating factor PAF; mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF-receptor antagonist L-652,731. J Immunol 1986;136:4659-68.
20. Hammerschmidt DE, Kotasek D, McCarthy T, Huh PW, Freyburger G, Vercelotti GM. Pentoxyphilline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988;112:254-63.
21. Stricter RM, Remick DG, Ward PA, Spengler RN, Lynch JP III, Larrick J et al. Cellular and molecular regulation of tumor necrosis factor alpha production by pentoxyphilline. Biochim Biophys Res Commun 1988;155:1230-6.
22. Rabinovici R, Yue T-L, Farhat M, Smith EF III, Esser KM, Slivjak M, et al. Platelet activating factor PAF and tumor necrosis factor-α TNF-aα interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist. J Pharm Exp Ther 1990;255:256-63.
23. Rossignol L, Plantavid M, Chap H, Douste-Blazy L. Effects of two methylxanthines, pentoxyphilline and propentophylline, on arachidonic acid metabolism in platelet stimulated by thrombin. Biochem Pharmacol 1988;37:3229-36.
24. Hardonk MJ, Dijkhuis FWJ, Hulstaert CE, Koudstaal J. Heterogeneity of rat liver and spleen macrophages in gadolinium chloride-induced elimination and repopulation. J Leukoc Biol 1992;52:296-302.
25. Iimuro Y, Yamamoto M, Kohno H, Itakura J, Fujii H, Matsumoto Y. Blockade of liver macrophages by gadolinium chloride reduces lethality in endotoxemic rats - analysis of mechanisms of lethality in endotoxemia. J Leukoc Biol 1994;55:723-8.
26. Sundaram R, O'Coonor M, Cicero M, Ghaffar A, Gangemi JD, Mayer EP. Lipopolysaccharide-induced suppression of erythrocyte binding and phagocytosis via FcγRI, FcγRII and FcγRIII, and CR3 receptors in murine macrophages. J Leukoc Biol 1993;54:81-7.
27. Wonderling RS, Ghaffar A, Mayer EP. Lipopolysaccharide-induced suppression of phagocytosois: effects on the phagocytic machinery. Immunopharmacol Immunotoxicol 1996;18:267-89.
28. Rabinovici R, Esser KM, Lysko PG, Yue T-L, Griswold DE, Hillegass LM, et al. Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res 1991;69:12-25.
29. Pignol B, Henane S, Sorlin B, Rola-Pleszcynski M, Mencia-Huerta JM, Braquet P. Effect of long-term treatment with platelet-activating factor on IL-1 and IL-2 production by rat spleen cells. J Immunol 1990;145:980-4.